{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
tapinarof
to a specific field?
There is one exact (name or code) match for tapinarof
Status:
US Approved Rx
(2022)
Source:
NDA215272
(2022)
Source URL:
First approved in 2022
Source:
NDA215272
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Tapinarof (also known as benvitimod, WB-1001; GSK-2894512), an investigational therapeutic aryl hydrocarbon receptor modulating agent that selectively modulates the cytokine cascade deep under the skin, a process that rapidly decreases inflammations and skin plague. Tapinarof participated in clinical trials for the treatment of psoriasis and atopic dermatitis. Phase III clinical trials to evaluate the efficacy and safety of the cream for the topical treatment of plaque psoriasis (psoriasis) was terminated because of the business decision based on the need to prioritize and focus resources within GSK. In July 2018, Roivant subsidiary Dermavant Sciences purchased the rights for tapinarof. Besides, tapinarof participated in phase II clinical trials for patients with atopic dermatitis.
Showing 1 - 6 of 6 results
Status:
US Approved Rx
(2022)
Source:
NDA215272
(2022)
Source URL:
First approved in 2022
Source:
NDA215272
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Tapinarof (also known as benvitimod, WB-1001; GSK-2894512), an investigational therapeutic aryl hydrocarbon receptor modulating agent that selectively modulates the cytokine cascade deep under the skin, a process that rapidly decreases inflammations and skin plague. Tapinarof participated in clinical trials for the treatment of psoriasis and atopic dermatitis. Phase III clinical trials to evaluate the efficacy and safety of the cream for the topical treatment of plaque psoriasis (psoriasis) was terminated because of the business decision based on the need to prioritize and focus resources within GSK. In July 2018, Roivant subsidiary Dermavant Sciences purchased the rights for tapinarof. Besides, tapinarof participated in phase II clinical trials for patients with atopic dermatitis.
Status:
Possibly Marketed Outside US
Source:
Octaplasma by Octapharma Pharmazeutika Produktionsges M B H [Canada]
Source URL:
First approved in 2013
Source:
BLA125416
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT03333824: Phase 1 Interventional Completed Solid Tumours
(2017)
Source URL:
Class:
PROTEIN
